The estimated Net Worth of Thomas William Burns is at least 33.3 百万$ dollars as of 8 January 2024. Mr. Burns owns over 60,115 units of Glaukos stock worth over 7,021,725$ and over the last 9 years he sold GKOS stock worth over 20,608,190$. In addition, he makes 5,716,560$ as President、 Chief Executive Officer、 Director at Glaukos.
Thomas has made over 44 trades of the Glaukos stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 60,115 units of GKOS stock worth 437,637$ on 8 January 2024.
The largest trade he's ever made was exercising 286,880 units of Glaukos stock on 6 August 2021 worth over 1,273,747$. On average, Thomas trades about 24,743 units every 33 days since 2015. As of 8 January 2024 he still owns at least 55,950 units of Glaukos stock.
You can see the complete history of Mr. Burns stock trades at the bottom of the page.
Thomas William Burns serves as President, Chief Executive Officer, Director of the Company. Mr. Burns has also been a member of the board of directors of DOSE Medical Corporation, serving as its chairman of the board, since October 2009 and served as its chief executive officer and president from March 2010 until June 2015. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, surgical products and over-the-counter products. Prior to joining our Company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer, and as a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery, of Bausch & Lomb from 1998 to 2000. Mr. Burns has also served as an entrepreneur in residence at Versant Ventures Management, LLC. Mr. Burns received a B.A. from Yale University. Mr. Burns currently serves as a director and as the chair of the compensation committee on the board of Avedro, Inc. (Nasdaq: AVDR).agreement terminated in its entirety upon the closing of our initial public offering.
As the President、 Chief Executive Officer、 Director of Glaukos, the total compensation of Thomas Burns at Glaukos is 5,716,560$. There are no executives at Glaukos getting paid more.
Thomas Burns is 59, he's been the President、 Chief Executive Officer、 Director of Glaukos since 2002. There are 5 older and 5 younger executives at Glaukos. The oldest executive at Glaukos Corporation is William Link, 74, who is the Independent Chairman of the Board.
Thomas's mailing address filed with the SEC is C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656.
Over the last 11 years, insiders at Glaukos have traded over 300,254,118$ worth of Glaukos stock and bought 17,376 units worth 317,262$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Gilbert H Kliman、Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of 8,240,079$. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth 96,000$.
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
Glaukos executives and other stock owners filed with the SEC include: